22 results about "Severe asthma" patented technology

This article describes a method for preventing or treating severe asthma by administering peptides associated with chaperone protein 60.1.

Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a pharmaceutical composition for treating hormone-resistant severe asthma and application of the pharmaceutical composition. The invention relates to an application of pentagalloylglucose (PGG) in preparation of a medicine for treating or preventing hormone-resistant severe asthma. The traditional Chinese medicine composition has a better effect on emphysema caused by severe asthma. The invention reveals and verifies that intestinal injury is a key upstream factor causing severe asthma and hormone resistance for the first time. Through targeted repair of intestinal tracts, the PGG can fundamentally remodel the immune microenvironment of the lung, and creates conditions for hormone to play a role. The discovery breaks through the limitation that traditional asthma treatment only focuses on local targets of the respiratory tract, and a brand new theoretical basis and a feasible solution are provided for overcoming the worldwide problem of hormone resistance.

The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.

Methods for treating patients with moderate-to-severe asthma comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Mucin 5AC (MUC5AC) gene. The MUC5AC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MUC5AC gene. Pharmaceutical compositions that include one or more MUC5AC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MUC5AC RNAi agents to pulmonary epithelial cells, in vivo, provides for inhibition of MUC5AC gene expression and a reduction in MUC5AC production, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including mucoobstructive lung disease such as severe asthma and various cancers.

The present invention provides compositions and related methods for treating interleukin-5 (IL-5) mediated diseases in children. [Solution] A method for treating a disease in a child, comprising the steps of: a) identifying a child weighing less than 40 kg who has a disease selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, etc.; and b) subcutaneously administering a therapeutically effective dose of mepolizumab to the child, wherein the therapeutically effective dose of the antibody results in a maximum plasma concentration (Cmax) of antibody of approximately 10.1960 ± 0.3345 μg / mL and an area under the curve [0-infinity] value of approximately 454.39 ± 15.8876 μg* / mL, thereby treating the disease in the child.

The present disclosure relates to antigen binding compositions, including antibodies, and related methods for treating interleukin 5 (IL-5) mediated diseases. IL-5 is a secreted protein. IL-5 plays a role in a variety of different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis, and severe atopic dermatitis. The disclosed compositions are suitable for treating these severe IL-5 mediated diseases.

The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and / or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and / or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality of respirable suspending particles.

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present disclosure provides a method for treating a subject having eosinophil-associated inflammation, such as severe asthma, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli labile toxin (LT).

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

The invention discloses application of an NTA10 inhibitor Remodelin in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The core pathological link of the allergic asthma is macrophage M2 polarization imbalance, and NAT10 serving as RNA N4-acetylcytidine modified write enzyme can drive the polarization process. Remodelin is used as an NAT10 specific inhibitor, and can be combined with an NAT10 catalytic structural domain to inhibit the activity of acetyltransferase in a targeted manner, so that an M2 polarization signal channel of macrophages induced by IL-4 / IL-13 is blocked. The invention provides an intraperitoneal injection type medicine taking Remodelin as a core active component, and in-vivo and in-vitro experiments prove that the medicine can remarkably reduce airway inflammatory cell infiltration, down-regulate inflammatory factor release, inhibit high secretion of mucus and airway remodeling, reduce the serum IgE level and effectively improve the pathology phenotype of allergic asthma. According to the invention, the asthma treatment value of the Remodelin-NAT10-macrophage M2 polarization regulation axis is disclosed for the first time, the blank of treating asthma through targeted RNA epigenetic modification is filled, and a brand new treatment scheme is provided for severe asthma.

The present disclosure relates to methods of treating severe asthma in a subject using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The present disclosure relates to a method of treatment of a subject having moderate or severe asthma, a method of improving lung function in a subject having moderate or severe asthma, and a method of selecting a subject having moderate or severe asthma for treatment with the anti-IL-33 antibody tozorakimab.

The present invention relates to a composition for co-administering Belzutifan, which is an HIF-2ɑ activity inhibitor having a steroid-resistant allergic airway inflammation reduction effect, and a steroid. The composition according to the present invention has the effect of alleviating inflammation and symptoms by co-administering an HIF-2ɑ inhibitor during the treatment of severe allergic asthma patients exhibiting steroid resistance. Thus, co-administering Belzutifan, which is an HIF-2ɑ inhibitor, and a steroid is a more effective treatment that can alleviate asthma and increase the quality of life of severe asthma patients.

The invention discloses a severe asthma treatment response and deterioration risk personalized early warning system, and the system comprises a data collection module which is used for carrying out the real-time monitoring of FeNO through a portable FeNO monitoring device, and uploading the data to a cloud server in real time through a matched mobile application; the trend identification module is used for smoothing the original FeNO data which are collected by the data collection module and are full of noise by using an LOESS algorithm, and matching the smoothed trajectory with a standard trajectory pattern library; the model construction module is used for learning FeNO dynamic characteristics of patients through Kalman filtering and constructing a dynamic prediction model for each patient; and the dynamic prediction module is used for predicting the normal fluctuation range of the FeNO at the next time point by using the trained dynamic prediction model, identifying an abnormal event and triggering early warning. Abnormal changes of the patient can be captured in time, the risk of disease deterioration can be recognized in advance, and precious time is won for clinical intervention.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

This disclosure relates to a method for treating a subject with moderate or severe asthma, a method for improving lung function in a subject with moderate or severe asthma, and a method for selecting a subject with moderate or severe asthma to be treated with the anti-IL-33 antibody tozolizumab.

The present disclosure provides a method for treating a subject having eosinophil-associated inflammation, such as severe asthma, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli labile toxin (LT).

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

The invention discloses an asthma patient machine emergency cloud scheduling method based on scene driving, and relates to the technical field of intelligent medical equipment and cloud computing. According to the method, by integrating asthma management all-in-one machine hardware equipment and a cloud scheduling platform, a collaborative system of multi-modal data acquisition, scenarized demand perception and dynamic resource allocation is constructed. The asthma management all-in-one machine is used for collecting physiological data, medical record images and medicine use records of a patient in real time and uploading the physiological data, the medical record images and the medicine use records to the cloud through a 5G / WiFi multi-module network. The cloud scheduling platform constructs a dynamic emergency scene model based on a knowledge graph technology, integrates individual features, induction factors and medical resource distribution, and generates a cooperative scheme of emergency ambulance scheduling, medicine distribution and remote consultation by taking the shortest response time, the lowest medical cost and the highest resource utilization rate as targets through an improved NSGA-III algorithm. The problems of information island, response lag and unreasonable resource allocation in a traditional asthma management system are solved, and the first-aid efficiency and treatment continuity of severe asthma patients are improved.